Company news
Liquidia Corporation news in 2020
Liquidia Corporation's news releases, calls and decks from 2020, newest first.
Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer
November 29, 2020
Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
November 24, 2020
Liquidia Closes Acquisition of RareGen
November 17, 2020
Liquidia Announces Results of Special Meeting of Stockholders
November 15, 2020
Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference
November 11, 2020
Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 8, 2020
Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC
November 1, 2020
Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
October 29, 2020
Liquidia Announces Postponement of Special Meeting of Stockholders
October 18, 2020
Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents
October 13, 2020
Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development
October 4, 2020
Liquidia Announces Special Meeting Date to Approve Proposed Acquisition of RareGen, LLC
September 16, 2020
Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil
August 27, 2020
Liquidia Announces Chief Financial Officer Transition
August 19, 2020
Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 9, 2020
Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 4, 2020
Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting
August 4, 2020
Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
August 2, 2020
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent
July 23, 2020
Liquidia Announces Closing of Public Offering of Common Stock
July 1, 2020
Liquidia to Host Conference Call to Provide Update on Recent Announcements
June 28, 2020
Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH
June 28, 2020
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents
June 4, 2020
Liquidia to Present at the Jefferies Virtual Healthcare Conference
May 26, 2020
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
May 17, 2020
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 10, 2020
Liquidia to Report First Quarter 2020 Financial Results and Provide Corporate Update on May 11, 2020
May 5, 2020
Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
April 29, 2020
Liquidia to Present at the 19th Annual Needham Healthcare Conference
April 8, 2020
Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
April 7, 2020
Liquidia Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
March 10, 2020
Liquidia to Report 2019 Financial Results and Provide Corporate Update on March 11, 2020
February 25, 2020
Liquidia to Present at Cowen 40th Annual Health Care Conference
February 25, 2020
Liquidia Submits New Drug Application for LIQ861 (treprostinil) inhalation powder to U.S. Food and Drug Administration for the Treatment of Pulmonary Arterial Hypertension (PAH)
January 26, 2020
Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
January 23, 2020